ELOXX PHARMACEUTICALS INC (ELOX) Stock Analyst Earnings Estimates
NASDAQ:ELOX - Nasdaq - US29014R2022 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 100K | 80K -20.00% | 80K | N/A -100.00% | 177.29M | ||||||||||
| EBITDA YoY % growth | -6.57M | -7.49M -14.00% | -5.32M 28.97% | N/A 11.65% | N/A -894.89% | -44.982M -7.93% | N/A 41.81% | N/A -124.39% | N/A 47.89% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -6.92M | -7.67M -10.84% | -5.41M 29.47% | N/A 12.38% | -45.449M -891.14% | -53.267M -7.62% | -37.052M 41.77% | -66.408M -124.25% | -35.7M 47.86% | -21.42M 37.77% | -28.56M -33.33% | -43.86M -53.57% | -56.1M -27.91% | 105.89M 288.75% | |
| Operating Margin | -6,920.00% | -9,587.50% | -6,762.50% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 59.73% | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | -57.15 | -55.87 2.90% | -37.74 47.01% | -38.35 5.63% | -16.97 38.36% | -8.07 51.16% | -7.54 6.57% | -6.78 10.01% | -8.20 -20.90% | 14.15 272.51% |
All data in USD
| Q3 / 23 | Q4 / 23 | |
|---|---|---|
| EPS Q2Q % growth | -2.01 44.18% | -1.46 50.05% |
| Revenue Q2Q % growth | ||
| EBITDA Q2Q % growth | N/A | N/A |
| EBIT Q2Q % growth | -4.08M 42.87% | -4.975M 17.48% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2023 Q2Q % growth | -1.96 59.17% | -1.57 | -0.39 | -24.78% |
| Q1 2023 Q2Q % growth | -2.88 44.62% | -2.60 | -0.28 | -10.73% |
| Q4 2022 Q2Q % growth | -2.92 47.86% | -3.03 | 0.11 | 3.61% |
| Q3 2022 Q2Q % growth | -3.60 18.18% | -4.49 | 0.89 | 19.79% |
| Q2 2022 Q2Q % growth | -4.80 40.00% | -4.22 | -0.58 | -13.86% |
| Q1 2022 Q2Q % growth | -5.20 40.91% | -3.77 | -1.43 | -37.78% |
| Q4 2021 Q2Q % growth | -5.60 6.67% | -4.90 | -0.70 | -14.38% |
| Q3 2021 Q2Q % growth | -4.40 31.25% | -5.51 | 1.11 | 20.12% |
| Q2 2021 Q2Q % growth | -8.00 | -5.61 | -2.39 | -42.60% |
| Q1 2021 Q2Q % growth | -8.80 -10.00% | -6.53 | -2.27 | -34.80% |
| Q4 2020 Q2Q % growth | -6.00 48.28% | -8.77 | 2.77 | 31.60% |
| Q3 2020 Q2Q % growth | -6.40 50.00% | -7.94 | 1.54 | 19.39% |
| Q2 2020 Q2Q % growth | -8.00 50.00% | -8.63 | 0.63 | 7.34% |
| Q1 2020 Q2Q % growth | -8.00 39.39% | -12.17 | 4.17 | 34.29% |
| Q4 2019 Q2Q % growth | -11.60 | -13.28 | 1.68 | 12.68% |
| Q3 2019 Q2Q % growth | -12.80 | -15.92 | 3.12 | 19.59% |
| Q2 2019 Q2Q % growth | -16.00 | -14.69 | -1.31 | -8.93% |
| Q1 2019 Q2Q % growth | -13.20 | -16.87 | 3.67 | 21.78% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2023 Q2Q % growth | 714K | -714K | -100.00% | |
| Q2 2022 Q2Q % growth | 2.38M | -2.38M | -100.00% | |
| Q1 2022 Q2Q % growth | 3.57M | -3.57M | -100.00% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | -4.23% | -10.63% | 4.24% |
| Revenue | N/A | -100% | N/A | -100% |